Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 East Medical Center Dr
3rd Floor Taubman Ctr Recp C
Ann Arbor, MI 48109Phone+1 734-647-7321- Is this information wrong?
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Cardiovascular Disease, 1992 - 1995
- University of Michigan Health SystemResidency, Internal Medicine, 1989 - 1992
- Northwestern University The Feinberg School of MedicineClass of 1989
Certifications & Licensure
- MI State Medical License 1991 - 2025
- IL State Medical License 1992 - 2005
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
- Eisenmenger Quality Enhancement Research Initiative Start of enrollment: 2012 Jul 01
- Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.Richard Channick, Kelly M Chin, Vallerie V McLaughlin, Matthew R Lammi, Roham T Zamanian, Stefano Turricchia, Rose Ong, Lada Mitchell, Nick H Kim> ;Cardiology and Therapy. 2024 Mar 7
- Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.Kim, N., MacDonald, G., Martin, N., Rosenberg, D., Solonets, M., Chin, K., McLaughlin, V., DuBrock, H., Restrepo-Jaramillo, R., Safdar, Z., Channick, R.> ;Pulmonary Therapy. 2024 Mar 1
- IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.Hunter Gillies, Benjamin T Dake, Jeremy P Feldman, Marius M Hoeper, Marc Humbert, Zhi-Cheng Jing, Jonathan Langley, Ralph W Niven, Stephan Rosenkranz, Xiaosha Zhang, M...> ;Pulmonary Circulation. 2024 Jan 1
- Join now to see all
Lectures
- Relieving the Pressure of Pulmonary Arterial Hypertension: Key Takeaways for the General Cardiologist Moving from Vague Symptoms to Ensuring Adequate Treatment Response2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Pulmonary Hypertension: From Etiology to Therapy2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Authored Content
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityFebruary 2018
Press Mentions
- Diagnosis and Treatment of Chronic Thromboembolic Pulmonary HypertensionSeptember 22nd, 2022
- Identifying and Navigating Challenging Clinical Scenarios in Pulmonary Arterial HypertensionAugust 25th, 2022
- CorVista Health Announces Drs. Vallerie v. McLaughlin and Mark G. Rabbat Join Medical Advisory BoardJune 8th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Michigan Medical CenterAnn Arbor, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: